Skip to content
10-Q

Quarterly Report

Seres Therapeutics, Inc. MCRB

0000950170-25-065173

← back to feed
Filed
May 7, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 2, 2025 8.73M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $58.85M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $30.79M
Current Liabilities Q1 2025 · Mar 31, 2025 $31.32M
Current Liabilities Q1 2025 · Dec 31, 2024 $41.22M
Total Liabilities Q1 2025 · Mar 31, 2025 $113.72M
Total Liabilities Q1 2025 · Dec 31, 2024 $126.03M
Current Assets Q1 2025 · Mar 31, 2025 $66.08M
Current Assets Q1 2025 · Dec 31, 2024 $38.67M
Total Assets Q1 2025 · Mar 31, 2025 $164.18M
Total Assets Q1 2025 · Dec 31, 2024 $139.81M
Shares Diluted restated Q1 2025 · Mar 31, 2024 7.31M sh
Capex Q1 2025 · Mar 31, 2024 $62K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$35.24M
Stockholders Equity Q1 2025 · Mar 31, 2024 −$59.74M
Stockholders Equity Q1 2025 · Dec 31, 2023 −$44.86M
Eps Diluted restated Q1 2025 · Mar 31, 2024 −$5.49
Eps Basic restated Q1 2025 · Mar 31, 2024 −$5.49
Sga Expense restated Q1 2025 · Mar 31, 2024 $14.94M
Rd Expense restated Q1 2025 · Mar 31, 2024 $19.49M
Net Income Q1 2025 · Mar 31, 2024 −$40.13M
Operating Income restated Q1 2025 · Mar 31, 2024 −$34.44M